首页> 外文OA文献 >Evaluating macrophage migration inhibitory factor 1 expression as a prognostic biomarker in colon cancer
【2h】

Evaluating macrophage migration inhibitory factor 1 expression as a prognostic biomarker in colon cancer

机译:评估巨噬细胞迁移抑制因子1表达作为结肠癌的预后生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: Several studies indicate that macrophage migration inhibitory factor 1 plays a role for tumor progression in colon cancer. We investigated whether determination of migration inhibitory factor 1 mRNA expression levels in lymph nodes of colon cancer patients could be used as a prognostic marker. Methods: Expression levels of migration inhibitory factor 1 and carcinoembryonic antigen mRNAs were assessed in primary tumors and regional lymph nodes of 123 colon cancer patients (stages I–IV), and in colon cancer- and immune cell lines using quantitative reverse transcriptase–polymerase chain reaction. Expression of migration inhibitory factor 1 protein was investigated by two-color immunohistochemistry and immunomorphometry. Results: Migration inhibitory factor 1 mRNA was expressed at 60 times higher levels in primary colon cancer tumors compared to normal colonic tissue (medians 8.2 and 0.2 mRNA copies/18S rRNA unit; p < .0001). A highly significant difference in mRNA expression levels was found between hematoxylin-eosin positive lymph nodes and hematoxylin-eosin negative lymph nodes (p < .0001). Migration inhibitory factor 1 and carcinoembryonic antigen proteins were simultaneously expressed in many colon cancer-tumor cells. Kaplan–Meier survival model and hazard ratio analysis, using a cutoff level at 2.19 mRNA copies/18S rRNA unit, revealed that patients with lymph nodes expressing high levels of migration inhibitory factor 1 mRNA had a 3.5-fold (p = .04) higher risk for recurrence, associated with a small, but significant, difference in mean survival time (7 months, p = .03) at 12 years of follow-up. Conclusion: Although migration inhibitory factor 1 mRNA expression levels were related to severity of disease and lymph node analysis revealed that colon cancer patients with high levels had a shorter survival time after surgery than those with low levels, the difference was small and probably not useful in clinical practice.
机译:目的:几项研究表明,巨噬细胞迁移抑制因子1在结肠癌中发挥肿瘤进展的作用。我们研究了结肠癌患者的淋巴结中迁移抑制因子1 mRNA表达水平的测定是否可以用作预后标志物。方法:在123例结肠癌患者(阶段I-IV)的原发性肿瘤和区域淋巴结和区域淋巴结和使用定量逆转录酶 - 聚合酶链中,评估迁移抑制因子1和癌胚胎抗原MRNA的表达水平,以及结肠癌和免疫细胞系反应。用双色免疫组织化学和免疫形状研究了迁移抑制因子1蛋白的表达。结果:与正常结肠组织(中位数8.2和0.2 mRNA拷贝/ 18s rRNA单位)相比,迁移抑制因子1 mRNA在原子结肠癌肿瘤中的60倍较高水平。在苏木精 - 嗜素阳性淋巴结和苏木精 - 曙红阴性淋巴结之间发现mRNA表达水平的高度显着差异(P <.0001)。在许多结肠癌肿瘤细胞中同时表达迁移抑制因子1和癌胚抗原蛋白。 Kaplan-Meier生存模型和危险比分析,使用2.19 mRNA拷贝/ 18s rRNA单元的截止水平,显示表达高水平的迁移抑制因子1 mRNA的淋巴结患者具有3.5倍(p = .04)复发的风险,与小而且显着,平均存活时间(7个月,P = .03)的差异有关的差异,随访12年。结论:虽然迁移抑制因子1 mRNA表达水平与疾病的严重程度有关,但淋巴结分析显示,患有高水平的结肠癌患者在手术后的存活时间较短,差异很小,可能没有用临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号